Leuven (BELGIUM) – December 23, 2013 – TiGenix (Euronext Brussels: TIG) announced today that it has signed a structured debt financing agreement of up to EUR 10 million with Kreos Capital (Kreos), Europe's largest an [...]
Dose confirmed for Phase Ib safety and efficacy expansion study
17 December 2013
Breda, The Netherlands / Ghent, Belgium – arGEN-X announces that the dose-escalation part of a Phase Ib study with its lead antibod [...]
Paris, 16 December 2013 – Hybrigenics (ALHYG), a bio-pharmaceutical company listed on the Alternext market of Euronext Paris, with a focus on research and development of new treatments against proliferative diseases, t [...]
HALLE/SAALE, Germany--(BUSINESS WIRE)-- Probiodrug AG (Probiodrug) and researchers from the Paul Flechsig Institute for Brain Research, University of Leipzig, Germany published results in the Journal of Alzheimer’s Dis [...]
Funds to advance ARGX-113, a novel antibody fragment approach to promote degradation and clearance of disease-causing autoantibodies, towards clinical development
4 November 2013
Breda, The Netherlands / Ghent [...]
4 November 2013
Breda, The Netherlands / Ghent, Belgium – arGEN-X today announced the signing of a research and license agreement with de Duve Institute/UCL (Belgium). Under the terms of the agreement, the parties w [...]
- Invention provides unique technology base for therapeutic human bispecific antibodies
- Full-length IgG format of bispecific antibodies facilitates standard manufacturing processes
Utrecht, The Netherlands, October [...]
+9% growth of Hybrigenics’ operating revenues
60% biological response rate of chronic lymphocytic leukemia patients to oral inecalcitol
US Patent protection for high dose inecalcitol until 2031
[...]
New cartridge detects 114 targets
Roll-out in collaboration with Heraeus Medical expected in early 2014
Holzgerlingen, Germany, October 22, 2013 -- Curetis AG today announced first details on its new Unyvero™ i60 [...]
Paris, 11 October 2013 – Hybrigenics (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new treatments of proliferative diseases and speciali [...]
Leuven (BELGIUM) – December 23, 2013 – TiGenix (Euronext Brussels: TIG) announced today that it has signed a structured debt financing agreement of up to EUR 10 million with Kreos Capital (Kreos), Europe's largest an [...]
Dose confirmed for Phase Ib safety and efficacy expansion study
17 December 2013
Breda, The Netherlands / Ghent, Belgium – arGEN-X announces that the dose-escalation part of a Phase Ib study with its lead antibod [...]
Paris, 16 December 2013 – Hybrigenics (ALHYG), a bio-pharmaceutical company listed on the Alternext market of Euronext Paris, with a focus on research and development of new treatments against proliferative diseases, t [...]
HALLE/SAALE, Germany--(BUSINESS WIRE)-- Probiodrug AG (Probiodrug) and researchers from the Paul Flechsig Institute for Brain Research, University of Leipzig, Germany published results in the Journal of Alzheimer’s Dis [...]
Funds to advance ARGX-113, a novel antibody fragment approach to promote degradation and clearance of disease-causing autoantibodies, towards clinical development
4 November 2013
Breda, The Netherlands / Ghent [...]
4 November 2013
Breda, The Netherlands / Ghent, Belgium – arGEN-X today announced the signing of a research and license agreement with de Duve Institute/UCL (Belgium). Under the terms of the agreement, the parties w [...]
- Invention provides unique technology base for therapeutic human bispecific antibodies
- Full-length IgG format of bispecific antibodies facilitates standard manufacturing processes
Utrecht, The Netherlands, October [...]
+9% growth of Hybrigenics’ operating revenues
60% biological response rate of chronic lymphocytic leukemia patients to oral inecalcitol
US Patent protection for high dose inecalcitol until 2031
[...]
New cartridge detects 114 targets
Roll-out in collaboration with Heraeus Medical expected in early 2014
Holzgerlingen, Germany, October 22, 2013 -- Curetis AG today announced first details on its new Unyvero™ i60 [...]
Paris, 11 October 2013 – Hybrigenics (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new treatments of proliferative diseases and speciali [...]
Follow us
